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Abstract
Background: To manage the risk factors and to improve clinical outcomes, patients with stroke commonly receive
multiple cardiovascular medications. However, there is a lack of evidence on the optimum combination of
medication therapy in the primary care setting after ischemic stroke. Therefore, this study aimed to investigate the
effect of multiple cardiovascular medications on long-term survival after an incident stroke event (ischemic stroke or
transient ischemic attack (TIA)).
Methods: This study consisted of 52,619 patients aged 45 and above with an incident stroke event between 2007
and 2016 in The Health Improvement Network database. We estimated the risk of all-cause mortality in patients
with multiple cardiovascular medications versus monotherapy using a marginal structural model.
Results: During an average follow-up of 3.6 years, there were 9230 deaths (7635 in multiple cardiovascular
medication groups and 1595 in the monotherapy group). Compared with patients prescribed monotherapy only,
the HRs of mortality were 0.82 (95% CI 0.75–0.89) for two medications, 0.65 (0.59–0.70) for three medications, 0.61
(0.56–0.67) for four medications, 0.60 (0.54–0.66) for five medications and 0.66 (0.59–0.74) for ≥ six medications.
Patients with any four classes of antiplatelet agents (APAs), lipid-regulating medications (LRMs), angiotensin-
converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), beta-blockers, diuretics and calcium
channel blockers (CCBs) had the lowest risk of mortality (HR 0.51, 95% CI 0.46–0.57) versus any one class. The
combination containing APAs, LRMs, ACEIs/ARBs and CCBs was associated with a 61% (95% CI 53–68%) lower risk
of mortality compared with APAs alone.
Conclusion: Our results suggested that combination therapy of four or five cardiovascular medications may be
optimal to improve long-term survival after incident ischemic stroke or TIA. APAs, LRMs, ACEIs/ARBs and CCBs were
the optimal constituents of combination therapy in the present study.
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Background
Stroke is the second most common cause of death
worldwide and the third most common cause of death
in the UK [1, 2]. According to Heart and Circulatory
Disease Statistics 2020, over 1.3 million people in the
UK have survived a stroke or transient ischemic attack
(TIA) [2]. Optimal pharmacological therapy plays a key
role in preventing the recurrence of stroke, cardiovascular
events and reducing the risk of mortality. To manage the
risk factors and to improve clinical outcomes, patients with
stroke commonly receive multiple cardiovascular medica-
tions. Guidelines recommend antihypertensive, lipid modi-
fication and antiplatelet agents for the secondary
prevention of stroke [3, 4]. The findings from the INTERS
TROKE study identified hypertension as the most import-
ant risk factor for stroke with a population-attributable risk
of 51.8% [5]. Evidence from a systematic review of rando-
mised controlled trials (RCTs) suggested that antihyperten-
sive treatment reduced recurrent vascular events by 21% in
patients after stroke [6]. A large systematic review of obser-
vational studies and RCTs supported a short-term outcome
benefit from statins [7]. Antiplatelet agents have been
shown to prevent death and vascular events in patients with
a high risk of cardiovascular disease [8], and dual antiplate-
let therapy was suggested to be more effective on short-
term outcomes than monotherapy in systematic reviews
[9–11]. Although in routine practice, most patients are on
combination therapy of multiple cardiovascular medica-
tions, the existing evidence from clinical trials has mostly
focused on a single cardiovascular medication. The effect of
combined antiplatelet agents and combined antihyperten-
sive medications was only assessed in clinical trials for the
prevention of stroke [12, 13].
A knowledge gap remains in identifying the optimal
combination of medication therapy after ischemic stroke.
It is unclear whether increasing the numbers or the clas-
ses of cardiovascular medications would have additional
benefits on long-term survival. Further, the optimal con-
stituents of combination therapy have not been compre-
hensively identified. This study aimed to investigate the
effect of multiple cardiovascular medications on long-




A cohort study was conducted using The Health Im-
provement Network (THIN) database (now known as
IQVIA Medical Research Data (IMRD)-UK database).
Database
THIN is a primary care database that contains anon-
ymised data from general practices across the UK. The
database includes over 16 million patients from over
744 general practices. In 2013, the active patients in
THIN represented approximately 6% of the UK popula-
tion [14].
THIN includes information for each individual on
demographics, diagnoses, prescriptions, referrals, labora-
tory tests, immunisations and the local area deprivation
score (Townsend score) [15]. Primary care physicians
and practice staff use a Read Code system to input and
distinguish diagnoses, symptoms, investigations and life-
style information in the electronic clinical notes. Pre-
scription data are recorded via drug codes, and these can
be identified by their generic name or by the British
National Formulary (BNF) chapter [16]. THIN data have
previously been used to study acute cardiovascular
events [17].
Study population
This study included patients with their first diagnosis of
ischemic stroke or TIA between January 2007 and
December 2016. Patients who were aged 45 or above
and who had been registered for at least 3 years in the
THIN database before the first stroke event were in-
cluded in this study. We excluded patients who had a
history of myocardial infarction (MI) before the first
stroke or TIA event, who had died of all causes or who
had an occurrence of a further cardiovascular event
within the first 90 days after the first event of stroke or
TIA. Follow-up of the included patients commenced at
the date of the incident stroke/TIA event and ended
until the earliest of 31 December 2016, date of registered
death and the date of leaving the general practice during
the study period. For each patient, the follow-up was di-
vided into contiguous periods of 1 year, each defined
with specific entry and exit points.
Exposures and controls
Cardiovascular prescriptions were identified using drug
codes in the THIN database. Each patient could contrib-
ute to several therapy categories, according to the car-
diovascular medications issued at each entry point.
Cardiovascular medications were identified based on all
medications classified in the British National Formulary
(BNF) Chapter 2 (cardiovascular system). Combination
preparations were separated into their individual drug
constituents.
We investigated the effect of combination therapy
based on different numbers, classes and combination
regimens on all-cause mortality. According to the num-
bers of cardiovascular medications (any medications
identified based on BNF) prescribed in each 90-day ex-
posure window, patients were stratified into groups of 0,
1, 2, 3, 4, 5 and ≥ 6 cardiovascular medications at each
entry point. We then selected six evidence-based classes
of cardiovascular medications commonly used for the
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secondary prevention of cardiovascular disease. The six
classes of cardiovascular medications were antiplatelet
agents (APAs), lipid-regulating medications (LRMs),
angiotensin-converting enzyme inhibitors (ACEIs)/
angiotensin receptor blockers (ARBs), beta-blockers
(BBs), diuretics (DRs) and calcium channel blockers
(CCBs) in stroke/TIA patients. Patients were stratified
into groups of 0 (none of any cardiovascular medication)
to 6 classes. Six classes of cardiovascular medications are
APAs, LRMs, ACEIs/ARBs, CCBs, DRs and BBs exclu-
sively. Patients who were on other class treatment were
excluded from the study due to the complexity of the
drug combination and few patients. Patients with one
drug treatment or one class drug treatment were consid-
ered as the control group.
Data extraction and confounders
Patient demographics, clinical characteristics within
1 year prior to each entry point and prescriptions within
3 months prior to each entry point were extracted from
the THIN database. Confounding variables included age,
gender, smoking status (never smoked, former smoker),
alcohol consumption (never drank, current drinker,
former drinker), body mass index (BMI) (mean, normal,
overweight, obese and underweight), blood pressure (BP)
status (normal; stage 1, 2 and 3 hypertension; and
hypotension), total cholesterol (TC) status (optimal,
intermediate and high), Townsend scores, history of
hypertension, hyperlipidaemia, arrhythmia, heart failure,
peripheral vascular disease, percutaneous transluminal
coronary intervention, diabetes, dementia, chronic ob-
structive pulmonary disease, asthma, liver disease, peptic
ulcer disease, rheumatoid arthritis and chronic kidney
disease. Previous use of cardiovascular medications and
nonsteroidal anti-inflammatory medications (NSAIDs)
were also included.
Statistical analysis
Data are summarised as mean (SD) for continuous vari-
ables and as frequencies (%) for categorical variables.
Comparisons were performed using analysis of variance
(ANOVA) for continuous variables and the chi-squared
test for categorical variables. Multiple imputation was
applied in addressing missing values for smoking status,
alcohol consumption, BMI status, BP status, TC status
and Townsend scores. We used multiple imputation by
chained equations (MICE) in SAS version 9.4 to create
25 imputed datasets [18]. Rubin’s rules were applied to
combine the results from analyses on each of the im-
puted datasets to produce estimates and confidence
intervals [19].
We estimated the risk of mortality presented as hazard
ratios (HRs) in relation to the number of medications,
medication classes prescribed and different combinations
using a marginal structural Cox proportional hazards
model, as described by Hernán et al. [20]. This method
aims to control for the effects of time-varying confounders
and treatment switching. We estimated the parameters of
our marginal structural model (MSM) by calculating a
weight for each person-year interval and fitting a weighted
pooled logistic regression model. Pooled logistic regres-
sion approximates the Cox model well when the risk of
events is less than 10% per person-time interval [21];
herein, the maximum entry-specific risk of all-cause mor-
tality was only 5.4%.
We used the inverse probability-of-treatment weight
and the inverse probability-of-censoring weight to adjust
for confounders at each entry point. In weight estimation,
the numerator included the time-dependent intercept and
the following baseline covariates: sex, baseline age, Town-
send score, history of comorbidities and previous cardio-
vascular medications. The denominator included the
time-dependent intercept, the baseline covariates and the
following time-varying covariates: age at each entry point,
most recently available smoking status, alcohol consump-
tion, BMI status, BP status, TC status, comorbidities and
previous occurrence of cardiovascular events (nonfatal
MI, angina, stroke or TIA) 1 year prior to each entry
point, and time-varying variables of previous cardiovascu-
lar medications and NSAIDs use 3 months prior to each
entry point.
Sensitivity analysis
We conducted several sensitivity analyses: (1) using a
60-day screening period instead of a 90-day window, (2)
dividing the 1-year follow-up time frame into intervals
of 6 months, (3) including patients who had a history of
MI before the first stroke or TIA event, (4) repeating the
analyses in patients with completed characteristics data
(complete-case analyses), (5) categorising missing data
for each covariate as a separate group, (6) repeating the
analyses separately for patients with TIA and patients
with ischemic stroke and (7) an additional sensitivity
analysis was conducted to assess the robustness of our
findings to unmeasured confounding by computing the
E value [22]. The E value is defined as “the minimum
strength of association, on the risk ratio scale, that an
unmeasured confounder must have with both the treat-
ment and the outcome to fully explain away a specific
treatment-outcome association, conditional on the mea-
sured covariates” [22]. All analyses were performed using
SAS version 9.4.
Results
The study cohort consisted of 25,200 men (47.9%) and 27,
419 women (52.1%) who experienced an initial ischemic
stroke or TIA event from 1 January 2007 to 31 December
2016. Overall, 8.1% of patients did not receive any
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cardiovascular medications, 9.2% received one, 20.3% re-
ceived two, 23.0% received three, 19.4% received four,
11.7% received five and 8.2% of patients received six or
more cardiovascular medications during the 90 days fol-
lowing their initial ischemic stroke or TIA event. The
mean age at the start of follow-up was 72.0 (SD, 11.9)
years, and the mean follow-up time was 3.6 (SD, 2.6)
years. In total, the study recorded 9230 deaths during
follow-up, and the crude death rate was 46.3/1000 person-
years. Table 1 shows the baseline characteristics of the pa-
tients at their initial ischemic stroke or TIA events based
on the number of cardiovascular medications received
during the first 90 days. There were significant differences
in all characteristics except peptic ulcer disease between
the groups.
Figure 1 shows the risk of all-cause mortality in pa-
tients prescribed with different numbers of cardiovascu-
lar medications. Compared with monotherapy, the risk
of all-cause mortality was lower in patients with combin-
ation therapy: 18% (95% CI 11–25%) lower with two
medications, 35% (95% CI 30–41%) lower with three
medications, 39% (95% CI 33–44%) lower with four
medications, 40% (95% CI 34–46%) lower with five
medications and 34% (95% CI 26–41%) lower with six
or more medications. Conversely, no use of cardiovas-
cular medications was associated with an increased risk
of all-cause mortality (adjusted HR 1.67, 95% CI 1.53–
1.82). Similar results were found for the different num-
bers of cardiovascular medication classes. Figure 2
shows the decreased risks of mortality in patients with
two (adjusted HR 0.79, 95% CI 0.73–0.86), three (ad-
justed HR 0.60, 95% CI 0.55–0.66), four (adjusted HR
0.51, 95% CI 0.46–0.57), five (adjusted HR 0.54, 95% CI
0.46–0.63) and six (adjusted HR 0.53, 95% CI 0.36–
0.77) specific classes of cardiovascular medications
compared with patients prescribed one class. Patients
with a four-class combination had the lowest risk of
mortality.
In the analysis of the effect of the 20 most commonly
used regimens containing APAs, LRMs, ACEIs/ARBs,
CCBs, DRs and BBs versus APAs alone, we found a
significantly lower risk of mortality in combinations
containing APAs, LRMs, ACEIs/ARBs and CCBs
(Fig. 3). In patients with the combination treatment
of APAs, LRMs, ACEIs/ARBs and CCBs, the risk of
mortality was lowered by 61% (95% CI 53–68%) com-
pared with APAs alone. When adding BBs or DRs to
this four-medication combination, the risk of mortal-
ity was lowered by 60% (95% CI 43–72%) and 59%
(95% CI 48–68%), respectively, when compared to
APAs alone. The combination of only three classes of
APAs, LRMs and ACEIs/ARBs also showed a signifi-
cantly lower risk of mortality with an adjusted HR of
0.44 (95% CI 0.38–0.51).
Sensitivity analyses
The results of sensitivity analyses are provided in
Additional file 1: Table S1-S2. Our primary results of
the risk of mortality in patients with different num-
bers of cardiovascular medications and different num-
bers of classes of cardiovascular medications are
similar to the results in the analysis using a 60-day
exposure window. The analyses in patients with a his-
tory of MI, patients with competing risk characteristic
data, when categorising missing data as a separate
group and in separate analyses among patients with
TIA only and patients with ischemic stroke only were
consistent with the results of primary analyses. The
results showed an even lower risk of mortality in pa-
tients with combination therapy when the follow-up
duration was divided into 6-month intervals. The E
values (risk ratios) for the three main analyses of all-
cause mortality ranged from 1.74 to 4.57.
Discussion
This cohort study is the first large, long follow-up
database-based study to report the effectiveness of in-
creasing numbers, classes and combinations of cardio-
vascular medications in the secondary prevention of all-
cause mortality in patients who experienced an incident
ischemic stroke or TIA. Our results showed that increas-
ing the numbers and classes of cardiovascular medica-
tions appeared to produce additional benefits on long-
term survival. APAs, LRMs, ACEIs/ARBs and CCBs ap-
peared to be the optimal constituents of combination
therapy associated with reduced risk of mortality after
stroke or TIA.
Previous studies have suggested the benefit of the
management of single risk factors such as hypertension,
high cholesterol and thrombus formation in the second-
ary prevention of stroke [6, 23, 24]. Our results strongly
suggest that multiple pharmacological interventions can
provide potentially greater benefits on long-term survival
for stroke patients. The results showed that HR of mor-
tality reached a plateau in patients with four (0.61, 95%
CI 0.56–0.67) or five (0.60, 95% CI 0.54–0.66) medica-
tions. Contrary to the combination therapy, patients
with no use of cardiovascular medications had a higher
risk of mortality. In summary, the combined use of four
or five cardiovascular medications in the present study
appeared optimal to improve long-term survival after
stroke.
Evidence-based guidelines recommend APAs, LRMs
and antihypertension medications for the secondary pre-
vention of stroke and TIA [25]. Diuretics, ACEIs/ARBs
and CCBs are first-line antihypertensive medications
[26]. Our study identified the priority of APAs, LRMs,
ACEIs/ARBs and CCBs in the secondary prevention of
stroke, which is consistent with the current guideline
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recommendations. This four-medication combination
was associated with a 61% reduction in mortality com-
pared with APAs alone. The 2-year retrospective cohort
study of Park and Ovbiagele [27] suggested that the
combination of antihypertensive medications, anti-
thrombotic medications and lipid modifiers was associ-
ated with a significant reduction of death following an
occurrence of stroke. The study classified several classes
of cardiovascular medications such as ACEIs/ARBs,
CCBs, DRs and BBs as antihypertensive medications.
However, our study did not find a significant additional
benefit when beta-blockers were added to the com-
bination therapy on long-term survival. This is in
line with a systematic review of RCTs [28], in which
no clear evidence supported a beneficial effect of
beta-blockers for secondary prevention of stroke or
TIA.
In addition, our results highlighted an issue that the
use of cardiovascular medications for the secondary pre-
vention of stroke and TIA remained sub-optimal. In our
study, 8.1% of patients did not receive long-term use of
cardiovascular medications, and 9.2% received only
monotherapy following their first stroke or TIA event.
Other studies in the UK population have also indicated
the underuse of evidence-based pharmacotherapy for
cardiovascular disease [29, 30]. We investigated demo-
graphics and clinical characteristics at each entry point
during the follow-up period. Patients with no or one
Fig. 1 Risk of all-cause mortality in patients prescribed cardiovascular medications. Mortality indicates unadjusted absolute risk per 1000 person-
years. Crude HR was assessed by an unweighted pooled logistic regression without any adjustment for confounding. Adjusted HR was assessed
by the MSMs adjusted for time-invariant and time-varying confounders
Fig. 2 Risk of all-cause mortality in patients prescribed six specific classes of cardiovascular medications. Mortality indicates unadjusted absolute
risk per 1000 person-years. Crude HR was assessed by an unweighted pooled logistic regression without any adjustment for confounding.
Adjusted HR was assessed by the MSMs adjusted for time-invariant and time-varying confounders
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cardiovascular medication were mostly at a relatively
lower risk of cardiovascular disease (e.g. younger age,
normal BMI status, with fewer comorbidities) compared
with patients with three or more drugs (Additional file 1:
Table S3). However, we could not rule out the missing
data issue here as aspirin is widely available over-the-
counter, and there may be some patients who had been
admitted to hospitals; therefore, the cardiovascular
medication during that period would not be available in
the GP record. Previous studies also have demonstrated
that cardiovascular risk levels [8], concerns on treatment
risk (e.g. side effects) [31] and patients preferences [32,
33] may explain the discrepancy between the guidelines
and real-world clinical practice. Our results have
strengthened the evidence for the long-term beneficial
effects of combined guideline-recommended cardiovas-
cular medications. We demonstrated that pharmacother-
apy in secondary prevention is necessary and beneficial
for individuals who have had a stroke regardless of the
risk level of cardiovascular disease. We suggest that
guideline compliance deserves better attention to improve
survival in patients with stroke or TIA.
Strengths and limitations
This study has several strengths. Firstly, this study was
based on a large population-based primary care practice
database. As such, it is likely to reflect the usual health-
care in the UK. Secondly, this study compared different
numbers, classes and combinations of cardiovascular
medications which comprehensively demonstrated the
effect of combination therapy on long-term survival.
Thirdly, when assessing the effect of different combina-
tions, we defined exposure groups as patients who were
exclusively using the selected cardiovascular medications
of interest, and this was to remove potential effects of
other cardiovascular medications which were not of
interest on the outcome. In addition, we used MSMs to
control for confounding due to both time-invariant and
time-varying confounders that may lead to treatment
switching or informative censoring. We demonstrated
Fig. 3 Risk of all-cause mortality in the 20 most commonly used regimens containing the six specific classes of cardiovascular medications
compared with antiplatelet agents alone. Mortality indicates unadjusted absolute risk per 1000 person-years. Crude HR was assessed by an
unweighted pooled logistic regression without any adjustment for confounding. Adjusted HR was assessed by the MSMs adjusted for time-
invariant and time-varying confounders
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the robustness of our findings to unmeasured confound-
ing using the E value estimate. Most HRs of all-cause
mortality for known, strong risk factors of cardiovascular
disease were below 1.74, the minimum E value in this
study. For example, the HRs of mortality were 1.61 (95%
CI 1.49–1.74) for current smokers, 1.27 (95% CI 1.19–
1.36) for patients with diabetes and 1.14 (95% CI 1.07–
1.20) for patients with hypertension. It is not likely that
an unmeasured or unknown confounder would have a
substantially larger effect on cardiovascular disease de-
velopment or mortality than these known risk factors by
having a relative risk exceeding 1.74. Finally, most com-
pellingly, we used all-cause mortality as our outcome
measure. Despite the influence of noncardiovascular
mortality on the outcome, our study produced very clear
results. Had we measured cause-specific cardiovascular
mortality, we suspect that our findings would have been
more pronounced.
This study has limitations. Firstly, the THIN database
only provides records of prescriptions; therefore, our
study was not able to determine if medications were ac-
tually dispensed, taken or used in line with the adminis-
tration directions by patients. Secondly, because the
THIN database does not capture data for hospital treat-
ment, treatment in some care homes or nursing homes,
and over the counter (OTC) medications (e.g. aspirin
available OTC), the study was not able to address any
medication usage not included in records from general
practice. Thirdly, we had no information on the severity
of stroke. Due to shorter life-expectancy, health inter-
ventions may be less cost-effective in patients with more
severe cardiovascular conditions [34, 35]. In this case,
patients with severe stroke may be more likely to be
undertreated and thus more likely to die. However, we
adopted measures to balance the heterogeneity between
different exposure groups to some extent: (1) we ex-
cluded patients who had a history of MI before the first
stroke event, (2) excluded patients who died or had a
nonfatal cardiovascular event during the first 90 days
after stroke or TIA and (3) we adjusted for risk factors
of cardiovascular disease when estimating mortality haz-
ard ratios. Fourthly, we only estimated the effect of car-
diovascular medications by their major classification so
our study cannot tell the effect of sub-classes of these
cardiovascular medications on long-term outcomes. For
instance, previous systematic reviews have suggested that
dual antiplatelet therapy was more effective on short-
term outcomes than monotherapy in stroke patients [9–
11], but our study did not compare the effect of dual-
antiplatelet therapy and monotherapy on long-term
mortality. Further research is required to explore this
area. In addition, the clinical guidelines of pharmaco-
therapy for secondary prevention of stroke had no major
changes over the period of 2007–2016 (refer to
guidelines from AHA/ASA 2006 [36], 2010 [37] and
2014 [4]; National clinical guideline for stroke 2008 [38],
2012 [39] and 2016 [40]). There are some changes of
recommendations on dosage and individual drugs. For
example, in terms of lipid-lowering therapy in secondary
prevention, the National Clinical Guideline 2008 recom-
mended using statins according to a recommended chol-
esterol level. Guideline 2012 recommended high-
intensity statin use such as atorvastatin 20–80mg daily
and Guideline 2016 recommended initiated using a sta-
tin with low acquisition cost such as simvastatin 40 mg
daily. Our study only focused on the numbers and clas-
ses of CV drugs and did not address the dosage issue in
the study due to the complexity of the research question
and analysis. There may be some residual confounding
impact on the mortality outcome in our study. But we
would expect this impact is minimal. Future studies on
drug dosage are encouraged.
Conclusions
Our study suggests that combination therapy of four or
five cardiovascular medications may be optimal for long-
term survival in patients with stroke or TIA. APAs,
LRMs, ACEIs/ARBs and CCBs were the optimal constit-
uents of combination therapy in the present study.
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